奥沙利铂联合多西紫杉醇治疗晚期非小细胞肺癌的临床观察

摘要

目的：观察奥沙利铂联合多西紫杉醇治疗晚期非小细胞肺癌的临床疗效及不良反应。方法：将晚期非小细胞肺癌患者68例随机分为两组，观察组34例采用奥沙利铂联合多西紫杉醇治疗，对照组34例采用顺铂联合多西紫杉醇治疗，进行疗效及不良反应比较观察，所有患者完成2个周期用药。结果：观察组总有效率(CR+PR)为47.1%，对照组总有效率(CR+PR)为41.2%，两组比较差异无统计学意义(P>0.05)。观察组恶心呕吐明显低于对照组(P<0.05)。结论：对于晚期非小细胞肺癌患者，使用奥沙利铂联合多西紫杉醇与使用顺铂联合多西紫杉醇进行比较，疗效相似，但使用奥沙利铂能有效改善患者的临床症状，副反应较轻，是值得临床推广的化疗方案。%Objective:To observe clinical efficacy and adverse reactions of advanced non-small cell lung cancer by docetaxel and oxaliplatin.Method:68 cases of non-small cell lung cancer patients were randomly divided into two groups.Observation group(34 cases) treated by docetaxel combined with oxaliplatin, control group(34 cases) treated with cisplatin combined with docetaxel,comparing curative effect observation.All the patients completed 2 cycles of drug using. Result:Observation group total effective rate(CR+PR) was 47.1%,control group total effective rate(CR+PR) was 41.2%,there was no statistically significant difference(P>0.05).Adverse reactions in two groups,nausea and vomiting observation group was obviously lower than the control group(P<0.05).Conclusion:For advanced non-small cell lung cancer patients,the use of oxaliplatin into joint docetaxel group and use cisplatin plus docetaxel group,curative effect is similar,but the use of oxaliplatin into group can effectively improve the patient’s clinical symptoms,the adverse event is lighter,is worthy of clinical promotion chemotherapy regimens.